https://doi.org/10.55788/465759fa
The study, presented by Dr Mark Thaller (University of Birmingham, UK), evaluated the impact of the severity of papilloedema on visual outcomes, as well as both visual and headache outcomes in a medically treated cohort of patients with IIH [1]. The researchers analysed data from 490 patients with a confirmed diagnosis of IIH from a longitudinal clinical examination dataset from the prospectively collected IIH: Life database 2012–2021; 98% were women and the mean body mass index (BMI) was 38 kg/m2.
The study focused on the key variables predicting vision and headache in 426 medically treated patients. Visual outcomes included visual acuity, perimetric mean deviation, and papilloedema, measured by optical coherence tomography (OCT) imaging. Headache outcomes were determined by the number of headache days per month and the headache impact test-6 (HIT-6) questionnaire.
The results showed that participants with the highest RNFL thickness on OCT had the worst visual outcomes. An important observation was a delay of more than 12 months before any decline became apparent in the visual field and OCT measurements. Regression analyses showed that the most important visual prognostic factors were:
- change in BMI (influencing visual field, RNFL, and macular GCL);
- disease duration (influencing RNFL and total retinal thickness); and
- diagnostic lumbar puncture opening pressure (influencing total retinal thickness).
The 281 participants who were managed medically and had active IIH experienced a high headache burden. Dr Thaller added that this burden showed a marked variability, with some patients struggling daily. Prognostic factors of headache were:
- daily headache at diagnosis (headache frequency, migraine-like headache frequency, and headache severity);
- personal history of migraine (headache frequency, migraine-like headache frequency, and headache severity);
- family history of migraine (headache severity); and
- disease duration (headache severity).
Dr Thaller claimed that these prognostic factors should be used in future trials and that targeted therapy remains an unmet clinical need.
- Thaller M, et al. The idiopathic intracranial hypertension prospective cohort study: evaluation of prognostic factors and outcomes. A16, EHC 2022, 07-10 December, Vienna, Austria.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Patients with migraines smoke less, drink less, and use fewer illicit drugs than general population Next Article
Periodontitis: An independent risk factor for AF »
« Patients with migraines smoke less, drink less, and use fewer illicit drugs than general population Next Article
Periodontitis: An independent risk factor for AF »
Table of Contents: EHC 2022
Featured articles
EHF consensus on effective migraine treatment and triptan failure
IHS President: “It is time for operationalisation of ICHD”
Headache Prophylaxis
Intervention
EHF consensus on effective migraine treatment and triptan failure
Sustained long-term effect of occipital nerve stimulation in MICCH
Onabotulinumtoxin A effective in older patients with chronic migraine
What to do when conventional treatment of headache fails in children
Predicting response to medical and surgical treatment of trigeminal neuralgia
Breakthroughs in Understanding Headache
IHS President: “It is time for operationalisation of ICHD”
GWAS identifies 7 loci for cluster headache
Towards precision medicine: salivary CGRP and erenumab response
Persistent headache after stroke: not rare and often overlooked
Additional effects of gepants on top of erenumab
Headache Prevention
Idiopathic intracranial hypertension: key factors influencing visual outcomes
Patients with migraines smoke less, drink less, and use fewer illicit drugs than general population
Related Articles
September 3, 2021
Impel NeuroPharma enters migraine market with FDA nod for nasal spray
August 27, 2019
The role of neurogenic inflammation in migraine
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com